FDA Reviews BPC-157, KPV, TB-500, and MOTS-c for the 503A Bulks List

The July 23, 2026 FDA review of BPC-157, KPV, TB-500, and MOTS-c was not an approval hearing and did not produce a final 503A Bulks List rule. FDA’s briefing documents describe preliminary agency evaluations, conducted on its own initiative after the underlying nominations had been withdrawn. The Pharmacy Compounding Advisory Committee’s role was to give non-binding expert advice.

That procedural frame is the central fact. Headlines that reduce the meeting to “FDA considered four peptides” lose the limits: FDA reviewed the free-base and acetate forms, in the context of named proposed uses, under a statutory process for pharmacy compounding.

Substance group	Forms FDA evaluated	Use evaluated at the meeting	FDA’s preliminary balance
BPC-157-related	Free base; acetate	Ulcerative colitis	Weighed against listing
KPV-related	Free base; acetate	Wound healing and inflammatory conditions	Weighed against listing
TB-500-related	Free base; acetate	Wound healing	Weighed against listing
MOTS-c-related	Free base; acetate	Obesity and osteoporosis	Weighed against listing

The table reports the official meeting agenda and FDA’s substance-specific briefings. “Weighed against” is FDA’s preliminary evaluation language. It is not a final legal determination.

Four reviews, four evidence records

BPC-157: FDA evaluated BPC-157 free base and BPC-157 acetate for ulcerative colitis. The BPC-157 briefing says the nomination materials were inconsistent about which bulk drug substance was intended, even though the free base and acetate are distinct ingredients. FDA noted that other proposed uses in the nominations did not contain enough information to evaluate and that it did not identify clinical studies in those populations. Its preliminary balancing of characterization, historical use, effectiveness, and safety criteria weighed against adding either evaluated form.

That is much narrower than a verdict on every claim attached to the name online. The current Jacked Forums BPC-157 reference describes the broader evidence landscape; the regulatory briefing asks a different question about specified bulk substances in 503A compounding.

KPV: The KPV briefing covers the free base and acetate in relation to wound healing and inflammatory conditions. FDA said neither form is a component of an FDA-approved drug and identified no applicable USP or National Formulary drug-substance monograph. Its document reports no adequate human effectiveness or safety information for the proposed context and reaches a preliminary balance against listing both forms.

The absence of adequate human information cannot be converted into proof that a substance is ineffective, nor into reassurance that it is safe. It means the review record did not support the case needed for this regulatory decision. Readers can separate this proceeding from the general KPV reference page, which is not a substitute for FDA’s briefing.

TB-500: FDA’s TB-500 document evaluated free-base and acetate forms for wound healing. It identified gaps in physical and chemical characterization, historical compounding evidence, and human safety and effectiveness evidence. The document also distinguishes TB-500 from broad references to thymosin beta-4; labels and related biological terminology do not make different substances interchangeable.

FDA’s preliminary balance again weighed against listing. That does not authorize a treatment protocol in the opposite direction, and the TB-500 reference should not be read as changing the agency proceeding’s status.

MOTS-c: The MOTS-c briefing evaluated free-base and acetate forms in the context of obesity and osteoporosis. FDA described rodent findings that had prompted scientific interest but said human exposure and clinical safety information were lacking. It also found no clinical studies providing pharmacokinetic data for the evaluated substances and reported that several other proposed uses could not be evaluated from the submitted information.

FDA warned that an absence of adverse-event reports would not establish safety, particularly because reporting from 503A compounders is generally incomplete. Its preliminary balance weighed against both forms. The site’s MOTS-c reference offers entity background, while this meeting record concerns whether the evaluated substances should enter a federal compounding list.

Why “free base or acetate” is not wordplay

Across the four briefings, FDA repeatedly treats a peptide free base and its acetate form as different bulk drug substances. They can share an active moiety yet have different chemical structures and physical, chemical, or pharmacokinetic properties. A common name on a sales page does not settle which ingredient is in a product.

This identity problem affects evidence interpretation. A study may use a name without clearly identifying the exact form. Nomination paperwork may point to one identifier while a certificate of analysis points to another. If the reviewed literature, proposed ingredient, and manufactured material cannot be linked with confidence, favorable findings cannot simply be transferred between them.

The FDA reviews also consider peptide-specific quality questions such as impurities, aggregation, stability, and possible immunogenicity. These are manufacturing and characterization issues that cannot be resolved by a vial label, a forum testimonial, or a statement of nominal purity.

What the 503A process can and cannot establish

Section 503A creates conditions under which qualifying compounded drugs may receive exemptions from certain federal requirements. The Bulks List process asks whether a bulk drug substance should be eligible for use under that framework when the relevant statutory conditions are considered. It is separate from the new-drug approval pathway.

The committee provides expert recommendations, but the meeting page explicitly says FDA is not legally bound by advisory committee advice. FDA must consider the process and complete its reviews before making a final determination. The withdrawn nominations did not stop the agency from evaluating these forms at its discretion, but they also should not be described as active sponsor requests.

Accordingly, the defensible reading is procedural and specific: in July 2026, FDA presented preliminary evaluations that weighed against adding the reviewed free-base and acetate forms for the stated use contexts. That sentence does not say FDA approved them, permanently banned them, evaluated every marketed derivative, or decided every scientific question involving their names.

It also provides no basis for cycles, doses, routes, stacks, or buying decisions. Those subjects are outside this report and outside what the advisory record can responsibly support.